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ABSTRACT 
 
Y-box proteins belong to the cold shock domain family of proteins that are known to be involved in both 
transcriptional and translational control. Here, we give a brief overview of the structure, regulation and 
physiological functions of the Y-box proteins. This is followed by examining the role of Y-box protein 1 
(YB-1), the most extensively studied of the Y-box protein in tumorigenesis, and its clinicopathological 
significance. YB-1 has the potential to be a prognostic marker and predictor of chemoresistance in human 
cancers. 
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INTRODUCTION 
 
Deregulation  of  proper  transcriptional  and  translational 
control  triggers  tumorigenesis.  Several  multifunctional 
proteins are involved in both transcriptional and transla-
tional control (Wilkinson and Shyu, 2001). Here we fo-
cus on a family of such multifunctional proteins, the Y-
box  protein  family,  in  terms  of  its  significance  in  cell 
proliferation and cancer. As different aspects of the Y-
box  proteins  have  already  been  reviewed  (Matsumoto 
and  Wolffe,  1998;  Swamynathan  et  al,  1998;  Evdoki-
mova  and Ovchinnikov,  1999; Kohno  et  al,  2003), we 
briefly appraise the structure and functions of the Y-box 
proteins with the emphasis on recent findings. We then 
summarize the role of a Y-box protein YB-1 in cancer 
and its use in the clinical setting. 
 
Y-box proteins (or Y-box binding proteins) are so named 
because they were originally identified as DNA binding 
proteins that are capable of associating with the Y-box 
(inverted CCAAT-box) sequence of the major histocom-
patibility  complex  class  II  gene.  Y-box  proteins  have 
thus far been known to regulate positively or negatively a 
number of genes, such as multidrug resistance 1, cyclin 
A,  cyclin  B1,  matrix  metalloproteinase  2  and  collagen 
alpha2(I)  (Higashi  et  al,  2003a;  Jurchott  et  al,  2003; 
Kohno et al, 2003). However, members of Y-box protein 
family  are  also  found  in  the  cytoplasm  and  associated 
with mRNAs as major components of messenger ribonu-
cleoprotein particles. Y-box proteins regulate translation 
in  a  dose-dependent  manner;  low  concentrations  of  Y-
box proteins activate translation and high concentrations 
repress it (Evdokimova and Ovchinnikov, 1999). Collec-
tively, Y-box proteins have been implicated in the regu-
lation of mRNA metabolism in multiple steps in both the 
nucleus and the cytoplasm, including transcription, splic-
ing, mRNA stability and translation. 
 
Structure and cellular localization of Y-box proteins 
Y-box proteins consist of three domains: the N-terminal 
domain,  the  cold  shock  domain  (CSD)  and  the  C-
terminal  tail  domain  (Figure  1).  The  CSD  is  a  highly 
conserved  nucleic  acid  binding  domain  that  confers 
RNA-  and  single-stranded  and  double-stranded  DNA 
binding activities to the Y-box proteins. Both the short 
N-terminal and the C-terminal tail domains are less con-
served  among  the  Y-box  proteins.  The  charged  C-
terminal tail domain of vertebrate Y-box proteins, con- 
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sisting of alternating clusters of acidic/aromatic and basic 
amino  acids,  is  likely  to  account  for  its  RNA-binding 
activity and ability for associating with various proteins. 
Y-box proteins have been shown to interact with a num-
ber  of  cellular  and  viral  proteins  that  are  involved  in 
various cellular processes (Figure 2). 
 
 
 
 
Figure 1. Schematic diagram depicting the structure of the Y-box protein. ++ and -- indicate clusters of basic and 
acidic/aromatic amino acids.  Functions attributed to each domain are summarized at the bottom. 
 
 
 
 
 
 
Figure 2. Cellular and viral proteins that interact with the Y-box protein. Numbers in parentheses indicate the references as 
follows: (1) Shnyreva et al, 2000, (2) Kohno et al, 2003; Swamynathan et al, 1998 and references therein, (3) Higashi et al, 
2003b, (4) Safak et al, 1999, (5) Zou et al, 1997, (6) Kojic et al, 2004, (7) Chansky et al, 2001, (8) Moraes et al, 2003, (9) 
Funke et al, 1996, (10) Raffetseder et al, 2003, (11) Wilhelm et al, 2000, (12) Matsumoto et al, 2005, (13) Balda et al, 2003, 
(14) Moorthamer et al, 1999, (15) Matsumoto and Wolffe, 1998; Evdokimova and Ovchinnikov, 1999 and references therein, 
(16) Balda and Matter, 2000, (17) Frankel et al, 2005.  
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In  a  variety  of  cell  types,  Y-box  proteins  are  predomi-
nantly found in the cytoplasm. However, given that Y-box 
proteins regulate transcription, they are expected to local-
ize to the nucleus. Y-box proteins are translocated into the 
nucleus by a number of conditions and mechanisms,  in-
cluding  UV  irradiation,  hyperthermia,  interferon-gamma 
treatment, adenovirus infection, interaction with p53 and a 
splicing  factor  SRp30c  and  high  levels  of  ectopic  YB-
1expression (Higashi et al, 2003a; Kohno 2003; Raffetse-
der et al, 2003 and references therein; Zhang et al, 2003). 
Both the CSD and the tail domains are implicated in nu-
clear localization of YB-1; the tail domain seems to con-
tain  a  non-canonical  nuclear  localization  signal  and  the 
isolated CSD also contributes to nuclear retention (Bader 
and Vogt,  2005). Y-box proteins are capable  of nucleo-
cytoplasmic shuttling, which allows them to contribute to 
the coupling control of transcription and translation. Y-box 
proteins  become  associated  with  nascent  transcripts  co-
transcriptionally and are presumed to accompany mRNA 
into  the  cytoplasm  (Soop  et  al,  2003).  Interestingly,  a 
mouse Y-box protein MSY2 preferentially associates with 
mRNAs that are transcribed from genes containing Y-box 
sequences  in  their  promoter  regions  and  stores  those 
mRNAs in male germ cells (Yang et al, 2005a). 
 
Regulation of the synthesis of Y-box proteins 
Experiments  with  overexpression  or  down-regulation  of 
the Y-box proteins in cultured cells or animals have shown 
that the amount of Y-box proteins must be precisely con-
trolled  (see  below).  Therefore,  it  is  important  to  under-
stand  how  the  synthesis  of  Y-box  proteins  is  regulated.  
Recent data have shown that the synthesis of a Y-box pro-
tein, YB-1 (Y-box binding protein-1), is regulated both at 
transcriptional  and  post-transcriptional  levels.  YB-1 
mRNA accumulates when cells are treated with cisplatin 
or UV irradiation (Ohga et al, 1996). Transcription of the 
YB-1 gene is stimulated by p73 through an enhanced re-
cruitment  of  the  c-Myc-Max  complexes  to  E-box  se-
quences  in  the  YB-1  promoter  (Uramoto  et  al,  2002).  
Once synthesized, YB-1 mRNA is negatively regulated by 
its own product. YB-1 protein represses translation of YB-
1 mRNA by binding to specific elements in the 5’- and 3’-
untranslated regions (Fukuda et al, 2004; Skabkina et al, 
2005). This self-regulation may contribute towards main-
taining the concentration of YB-1 protein optimal in a cell. 
 
Physiological functions of Y-box proteins 
In human and mouse, there are three Y-box proteins, two 
of  which  are  expressed  in  both  somatic  cells  and  germ 
cells (Table 1). The most extensively studied Y-box pro-
tein,  YB-1,  is ubiquitously  expressed  in  various  tissues.  
Human Contrin and mouse MSY2 are germ cell-specific 
members  of  the  Y-box  protein  family.  Analyses  of  the 
effects of targeting Y-box genes in chicken cells and mice 
have  been  widely  carried  out  in  the  last  three  years.  
Chicken B-cell lymphoma DT40 cells are widely used to 
study functional consequences of disrupting specific genes 
because of the high frequency of homologous recombina-
tion. The YB-1 (or YB-1b) gene in DT40 cells has been 
disrupted by two independent groups of investigators; one 
group reported that YB-1
+/- cells show slow-growth phe-
notype and increased DNA content (Swamynathan et al, 
2002). The other group of researchers found that heterozy-
gous disruption resulted in no growth defects but homozy-
gous gene disruptants exhibited a slow and cold-sensitive 
growth phenotype (Matsumoto et al, 2005). One research 
group tried to disrupt YB-1 gene in mice but encountered 
difficulties  in  disrupting  both  alleles  of  the  YB-1  gene 
(Shibahara et al, 2004). They found hypersensitivity of the 
YB-1
+/- cells to genotoxic stresses. However, as was the 
case in chicken cells, another group recently reported ho-
mozygous YB-1gene disruption, showing the importance 
of YB-1 in late stages of embryonic development (Lu et al, 
2005).  They  observed  developmental  defects  of  YB-1
-/-
embryos after embryonic day 13.5 including craniofacial 
lesions, hemorrhage and respiratory failure, with YB-1
-/- 
MEF cells showing premature senescence and hypersensi-
tivity to different cellular stresses. The reason for the pres-
ence  or  absence  of  the  haplo-insufficient  phenotypes  is 
currently unknown.  In mice lacking MSY2, both male and 
female  homozygotes  are  sterile,  a  consequence  of  dis-
turbed  spermatogenesis  due  to  reduction  of  postmeiotic 
germ-cell  mRNAs  in  male  and  oocyte  loss  in  female 
(Yang et al, 2005b). Overall, studies designed to reduce or 
deplete a Y-box protein in cells or whole organisms under-
score the significance of Y-box proteins in appropriate cell 
growth, stress responses and development. 
 
 
Table 1. Y-box proteins in human and mouse 
 
Human  Mouse  Expression  Phenotype in 
knockout mice 
YB-1/DbpB  YB-1/MSY1  Ubiquitous  Embryonic/perinatal 
lethality (neurologi-
cal abnormalities, 
haemorrhage, respi-
ratory failure and 
growth retardation)* 
DbpA  MSY4  Ubiquitous 
(abundant in 
heart, mus-
cle and 
testis) 
Unknown 
Contrin  MSY2  Germ cells  Male and female 
infertility** 
 
*Lu et al, 2005 
**Yang et al, 2005b 
 
 
Role of YB-1 in tumorigenesis 
The role of YB-1 in cancer progression has attracted atten-
tion in recent years.YB-1 has been found to be upregulated 
during  prostate  cancer  tumor  progression  (Gimenez-
Bonafe et al, 2004). Increased YB-1 expression has been 
correlated with DNA topoisomerase IIα and proliferating 
cell nuclear antigen expression in human lung cancer (Gu 
et al, 2001) and colorectal cancer (Shibao et al, 1999) and 
linked to markers of cellular proliferation in osteosarcoma 
(Oda et al, 1998). YB-1 has been identified as a cell cycle 
stage-specific  transcription  factor  (Jurchott  et  al,  2003). 
Nuclear accumulation of YB-1 in HeLa cells was demon-
strated to transcriptionally activate cyclin A and B1 genes, 
which are crucial for cell cycle progression. Increase in 
cyclin  A  has  been  reported  to  be  associated  with  poor 
clinical outcome in breast cancer (Michalides et al, 2002).  
 
In  addition,  YB-1  is  believed  to  promote  metastasis  by 
enhancing the transcription of gelatinase A, a matrix met- 
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alloproteinase that facilitates cell migration (Cheng et 
al,  2002).    Recently,  Berquin  et  al.  (2005)  has  also 
shown that YB-1 may induce epidermal growth factor 
(EGF)  independence  in  mammary  epithelial  cells  via 
activation  of  the EGF receptor  pathway,  thereby  con-
tributing to breast tumor aggressiveness. In yet another 
recent paper, Bergmann and colleagues (2005), using a 
transgenic mouse model, showed that overexpression of 
YB-1 may cause breast cancer through the
 induction of 
genetic instability. 
 
On the other hand, YB-1 may have anti-oncogenic activ-
ity as it is reported to be capable of blocking oncogenic 
cell transformation (Bader and Vogt, 2005). The phos-
phoinositide 3-kinase (PI 3-kinase) pathway is known to 
show gain of function in human cancers (Bader and Vogt 
2004).  The catalytic  subunits of  PI  3-Kinase,  p110  (of 
which P3K is  a homolog) and Akt are oncoproteins and 
YB-1  is  specifically  known  to  inhibit  P3K  and  Akt-
induced  transformation  involving  protein  synthesis 
(Bader et al., 2003). YB-1 may interefere with the syn-
thesis  of  growth-related  proteins  including  growth  fac-
tors, receptors, kinases, transcriptional regulators and cell 
cycle proteins  associated with P3K and Akt pathways 
(Zimmer et al, 2000; Bader and Vogt 2004). 
 
A  seminal  paper  describing  YB-1  expression  in  cancer 
tissues was first reported by Royer’s group in breast can-
cer (Bargou et al, 1997). The pathological significance of 
YB-1 in a variety of cancers is shown in Table 2. 
 
 
 
Table 2. Overexpression of  YB-1 and pathological significance in human cancers 
 
Organ  Tumors  Pathological Significance  Reference 
 
Breast 
 
Invasive ductal breast cancer 
 
 
 
 
 
Breast cancer (histologic subtype not speci-
fied) 
 
Tumor aggressiveness and axillary lymph node 
positivity 
 
Associated with progesterone receptor positivity 
but no prognostic value 
 
Higher risk for relapse without postoperative 
chemotherapy 
 
 
Huang et al, 2005 
 
 
Saji et al, 2003 
 
 
Janz et al, 2002 
 
Ovary 
 
Surface epithelial neoplasms (serous, muci-
nous, endometroid & clear cell) 
 
Surface epithelial neoplasms (mainly serous) 
 
 
Serous adenocarcinoma 
 
Co-expression with P-glycoprotein associated 
with poor survival 
 
Higher  nuclear expression in recurrent lesions 
than in primary tumors 
 
Poor prognosis 
 
 
Huang et al, 2004 
 
 
Yahata et al, 2002 
 
 
Kamura et al, 1999 
 
Lung 
 
Nonsmall cell lung cancer 
 
 
 
 
 
Squamous cell carcinoma 
 
Adenocarcinoma 
 
 
Nuclear expression correlated with reduced sur-
vival 
 
Nuclear expression correlated with  node metas-
tasis, stage of the disease and poor prognosis 
 
Poor prognosis 
 
Associated with T3-4 and Stage II-IV tumors 
 
Gessner et al, 2004 
 
 
Shibahara et al, 2001 
 
 
Shibahara et al, 2001 
 
Gu et al, 2001 
 
 
Thyroid 
 
Anaplastic (undifferentiated) carcinomas, 
papillary carcinomas and follicular carcinomas 
 
 
High expression in anaplastic carcinoma (known 
to be rapidly progressive)  
 
 
Ito et al, 2003 
 
 
Soft tissues 
 
 
Synovial sarcoma 
 
 
Poor prognosis 
 
 
Oda et al, 2003 
 
 
Large intestine 
 
 
Colorectal adenocarcinoma 
 
Proliferation associated marker 
 
Shibao et al, 1999  
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YB-1 and chemoresistance in human tumors 
Substantial  YB-1  expression  was  demonstrated  in  mul-
tidrug-resistant  breast,  gastric  and  pancreatic  cell  lines 
(Holm et al, 2004). Altered drug sensitivity to cisplatin, a 
very potent and widely used anti-cancer agent and mito-
mycin C has been observed following treatment of cells 
with  antisense  YB-1  (Ohga  et  al,  1996;  Torigoe  et  al, 
2005). Expression of YB- 1 protein has been reported to 
reflect the chemosensitivity of ovarian serous adenocarci-
noma (Kamura et al, 1999) and breast cancer (Janz et al, 
2002; Huang et al, 2005). Increased nuclear localization of 
YB-1  has  been  observed  in  acquired  cisplatin-resistant 
ovarian cancer (Yahata et al, 2002). 
 
YB-1  expression  has  also  been  shown  to  be  associated 
with P-glycoprotein (Pgp) expression in breast cancer cells 
resulting in drug resistance (Bargou et al, 1997; Saji et al, 
2003;  Huang  et  al,  2005).  Pgp,  encoded  by  the  MDR1 
gene, is a member of the ATP-binding cassette transporter 
superfamily of proteins involved in the protection of cells 
from xenobiotics and drugs (Kuwano et al, 2003). Pgp has 
become an important molecular target for limiting chemo-
resistance as it plays a major role in the development of 
multidrug-resistant tumor type and  is  known to mediate 
resistance to a wide range of anticancer agents (Kuwano et 
al, 1999). Bay and co-workers have recently demonstrated 
a direct interaction between YB-1 and Pgp using the com-
puter-based Resonance Recognition Model (Huang et al, 
2005). The same investigators observed the occurrence of 
raised recurrence rates in breast tumor patients with high 
YB-1 expression who underwent a chemotherapy regime 
which contained anthracycline (a Pgp substrate). Besides 
breast cancer, YB-1 has been correlated with Pgp in ovar-
ian cancer (Huang et al, 2004), prostate cancer (Gimenez-
Bonafe et al, 2004) and osteosarcoma (Oda et al, 1998). 
 
YB-1 has been shown to bind p53 (Okamoto et al, 2000) 
and interaction with p53 could be necessary for the self-
defense of cells exposed to DNA-damaging agents (Ku-
wano et al, 2003). As mentioned earlier, p73, a close rela-
tive of the p53 family, has also been observed to stimulate 
transcription of the YB-1 promoter by enhancing the re-
cruitment  of  the  cMyc-Max  complex  to  its  target  gene 
(Uramoto et al, 2002). c-Myc, an oncogene with a dual 
function  in  cell  proliferation  and  apoptosis  can    confer 
resistance to cisplatin. p73 is known to induce apoptosis 
(Irwin et al, 2000). and p73 overexpressing clones have 
been observed to be cisplatin resistant (Gong et al, 1999). 
Hence, c-Myc and p73 may form a complex necessary in 
YB-1 mediated drug resistance (Uramoto et al, 2002).  
 
CONCLUSIONS 
 
Expression of the YB-1 protein has a prognostic signifi-
cance in determining disease progression in human can-
cers. Perhaps more importantly, YB-1 has the potential to 
be a biological marker which predicts chemotherapy resis-
tance and aid in the selection of appropriate adjuvant che-
motherapy.  There  has  been  cumulative  evidence  in  the 
literature to suggest that YB-1 is involved in pleiotropic 
resistance    to  different  classes  of  DNA-targeting  drugs 
(Levenson et al, 2000). As clinical drug resistance ham-
pers  effective  chemotherapy,  a  recent  focus  in  cancer 
therapeutic strategy is to develop molecular cancer thera-
peutics (Kuwano et al, 2003; Holm et al, 2004). In this 
regard, YB-1 holds promise as target molecule for the de-
velopment of novel approaches in overcoming multidrug 
resistance in cancer chemotherapy (Janz et al, 2002).  
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